<DOC>
	<DOC>NCT02382016</DOC>
	<brief_summary>24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.</brief_summary>
	<brief_title>PORtopulmonary Hypertension Treatment wIth maCitentan â”€ a randOmized Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Main Male or female of at least 18 years of age Confirmed diagnosis of portopulmonary hypertension Main Severe hepatic impairment Severe obstructive or restrictive lung disease Pulmonary venoocclusive disease Systolic blood pressure (SBP) &lt; 90 mmHg at Screening ALT/AST &gt;= 3 x ULN Bilirubin &gt;= 3 mg/dL at Screening Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>